Haemophilus Influenzae Type B

Mechanism-of-action class: Immunologic Factor Interactions.

• Directions : pour the content of 1 tube directly into the mouth and allow to dissolve under the tongue. Take on an empty stomach.

Adults and children 6 years and older: take 1 tube every 6 hours, up to 3 times per day. Children under 6 years: Ask a doctor.

Stop use and ask doctor if symptoms persist more than 5 days or worsen. If pregnant or breast-feeding ask a health professional before use. Keep out of reach of children.

Recent PubMed references pinned to Haemophilus Influenzae Type B as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.

• Post-marketing safety surveillance of Haemophilus influenzae Type b conjugate vaccine in children aged 3 months to 5 years in Jiangsu, China.
  Human vaccines & immunotherapeutics · 2026 · Zhou Y, Tang R, Wei M, et al.
  PMID 42216576DOI 10.1080/21645515.2026.2677876
• Product- and schedule-specific vaccine effectiveness against invasive Haemophilus influenzae serotype b (Hib) disease, The Netherlands, 2005 to 2023.
  Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026 · Bertran M, de Gier B, Garcia Vilaplana T, et al.
  PMID 42141871DOI 10.2807/1560-7917.ES.2026.31.19.2500699
• Characteristics of an uncommon sequence type of serotype b Haemophilus influenzae causing an increase in invasive disease in British Columbia, Canada.
  Journal of infection and public health · 2025 · Tsang RSW, Grant J, Liu L, et al.
  PMID 41110443DOI 10.1016/j.jiph.2025.102991
• Infant protection from invasive Haemophilus influenzae type b disease using the PRP-OMPC conjugate vaccine: An update.
  Human vaccines & immunotherapeutics · 2025 · Taha MK, Marcek T, Chapman TJ, et al.
  PMID 40919685DOI 10.1080/21645515.2025.2553949
• [Analysis of pathogenic features of mucoid Haemophilus influenzae infection in children].
  Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine] · 2025 · Liu JL, Deng M, Song CR, et al.
  PMID 40829915DOI 10.3760/cma.j.cn112150-20250331-00260
• Late initiation of pneumococcal and Haemophilus influenzae type b vaccinations.
  Vaccine · 2025 · Albers AN, Fox ER, Michels SY, et al.
  PMID 40829385DOI 10.1016/j.vaccine.2025.127611
• Increase in invasive Haemophilus influenzae type b disease in young children despite high vaccination coverage, France, 2018-2024.
  Vaccine · 2025 · Barret AS, François C, Deghmane AE, et al.
  PMID 40683138DOI 10.1016/j.vaccine.2025.127499
• Clinical progress note: Haemophilus influenzae type b.
  Journal of hospital medicine · 2025 · Ewing A, Haldeman S, Ratner AJ, et al.
  PMID 40205699DOI 10.1002/jhm.70059

The 10 most recently updated of 345 ClinicalTrials.gov registrations naming Haemophilus Influenzae Type B as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.

• BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies
  Recruiting · Phase 3 · Interventional · 6,000 enrolled · Pfizer
  NCT07160244updated 2026-06-09
• A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants
  Active not recruiting · Phase 2 · Interventional · 215 enrolled · GlaxoSmithKline
  NCT06213506updated 2026-05-19
• Infant Malaria Vaccine Schedule Optimization
  Recruiting · Phase 2 · Interventional · 964 enrolled · PATH
  NCT06879327updated 2026-05-15
• Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children
  Completed · Phase 4 · Interventional · 347 enrolled · Duke University
  NCT06038617updated 2026-05-13
• Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines
  Completed · Phase 1 · Interventional · 594 enrolled · University of Oxford
  NCT05155579updated 2026-04-08
• Integrating Point of Care Testing (POCT) For Newborn Screening and Early Care for Sickle Cell Disease in Yopougon, Côte d'Ivoire
  Not yet recruiting · Phase 4 · Interventional · 120 enrolled · Swiss Tropical & Public Health Institute
  NCT07488520updated 2026-03-23
• Exploratory Clinical Study of MT-2301
  Completed · Phase 2 · Interventional · 154 enrolled · Tanabe Pharma Corporation
  NCT02140047updated 2026-03-17
• Testing the Effectiveness and Implementation of a Meditation App for Youth in the Legal System
  Recruiting · Interventional · 300 enrolled · University of Illinois at Chicago
  NCT06997120updated 2026-03-10
• A Study Assessing the Safety, Efficacy, and Impact of GlaxoSmithKline Biologicals' RTS, S/AS01E Malaria Vaccine in Young Children Across Sub-Saharan Africa
  Completed · Observational · 77,953 enrolled · GlaxoSmithKline
  NCT03855995updated 2026-03-02
• Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants
  Completed · Phase 3 · Interventional · 1,196 enrolled · GlaxoSmithKline
  NCT03621670updated 2026-02-10

Frequently asked questions

How does Haemophilus Influenzae Type B work?

Mechanism-of-action class: Immunologic Factor Interactions.

What is Haemophilus Influenzae Type B used for?

According to FDA labeling, Haemophilus Influenzae Type B carries indications including: Directions : pour the content of 1 tube directly into the mouth and allow to dissolve under the tongue. Take on an empty stomach.. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.

What class of drug is Haemophilus Influenzae Type B?

Haemophilus Influenzae Type B is classified as Immunologic Factor Interactions, Increased Antibody Production.